Microbio announced that it has received the approval of Imported Drug License from Macao Special Administrative Region (SAR), for its chemotherapy adjuvant drug, Chemo Young oral solution. Chemo Young is a proprietary drug developed by the Microbio in accordance to international drug development regulations and received new drug approval from the Taiwanese Food and Drug Association (TFDA) in 2011. Microbio is currently expanding its market, and the importation approval from Macao represents the first step of reaching the markets in Greater China Region.
Microbio is a biotech undergoing a transition from R&D into commercialization. Microbio has led to two successful new drug approvals by the TFDA, Chemo Young and Herbiron. Herbiron was approved for indication to improve primary dysmenorrhea and iron-deficiency anemia in women. To date, the TFDA has approved four new drug applications.
Microbio utilizes its proprietary fermentation platform to develop its first TFDA-approved new drug, Chemo Young. It represents a first-ever oral drug indicated to fatigue and appetite loss associated with chemotherapy.
In Taiwan, Harvester is the exclusive agent to distribute Chemo Young as an Over-the-Counter drug. The Chairman of Microbio, Dr. Willie Lin stated that Macao is an interesting market with substantial international access, the tourism mount to 25 to 30 million travelers per year, and offers tax-free for imported goods. In another word, it is full of business potential. In addition, its unique relationship with China may aid the drug approval by the Chinese FDA (CFDA) for Microbio.